title: Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
authors.forename: S
authors.initials: S
authors.lastname: De Vita
authors.forename: S
authors.initials: S
authors.lastname: De Matteis
authors.forename: L
authors.initials: L
authors.lastname: Laurenti
authors.forename: P
authors.initials: P
authors.lastname: Chiusolo
authors.forename: F
authors.initials: F
authors.lastname: Sorà
authors.forename: N
authors.initials: N
authors.lastname: Piccirillo
authors.forename: G
authors.initials: G
authors.lastname: Reddiconto
authors.forename: A
authors.initials: A
authors.lastname: Fiorini
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: S
authors.initials: S
authors.lastname: Sica
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001932:Brain Neoplasms / Q000188:drug therapy*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000235:genetics; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate